Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition

A technology of composition and water-based composition, which is applied in the direction of drug combination, drug delivery, non-active ingredients of polymer compounds, etc.

Pending Publication Date: 2021-06-25
SEIKAGAKU KOGYO CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These target both immediate pain relief and long-term pain relief by improving functional impairment, but are still in the development stage and have not yet been licensed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition
  • Pharmaceutical composition
  • Pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0196] Preferred embodiments of the present invention are exemplified below.

[0197] [1] A pharmaceutical composition comprising a compound represented by formula (1) and component (A):

[0198] Component (A): selected from nonionic surfactants, hydroxyalkylated cyclodextrins, C 1 ~C 3 Monohydric alcohol, C 2 ~C 3 Diol, C 3 ~C 6 At least one compound selected from the group consisting of triols, polyalkylene glycols, γ-lactones, polyvinylpyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof,

[0199]

[0200] In formula (1), a is not less than 0.01 and not more than 0.7, a+b is 1, n is an integer not less than 25 and not more than 25000, and the arrangement of each disaccharide structural unit is optionally random or block-like. R in the sugar structural unit is each independently a carboxyl group or a carboxylate group.

[0201] [2] The pharmaceutical composition according to [1] above, wherein the component (A) is selected from the group consisting of ...

Embodiment

[0279] Hereinafter, preferred embodiments of the present invention will be described in more detail using examples, but the present invention is not limited at all by the following examples.

Synthetic example

[0281]According to the method described in the examples of International Publication No. 2005 / 066214, hyaluronic acid derivatives (compounds represented by formula (1)) were synthesized (a: 0.18, n: 2 k, the mass average molecular weight of hyaluronic acid :800 000).

[0282] More specifically, it was synthesized by the following method.

[0283] Dissolve 2.155 g (10.5 mmol) of 2-bromoethylamine hydrobromide in 20 mL of dichloromethane, add 1.463 mL (10.5 mmol) of triethylamine under ice-cooling, and then add di-tert-butyl dicarbonate (Boc 2 O) 5 mL of a dichloromethane solution of 2.299 g (10.5 mmol) was stirred. After stirring at room temperature for 90 minutes, ethyl acetate was added, followed by liquid-separation washing with a 5% by weight aqueous citric acid solution, water, and saturated brine. After dehydration with sodium sulfate, the solvent was distilled off under reduced pressure to obtain Boc-aminoethyl bromide.

[0284] Ice-cool 5 mL of a dimethylformamide (D...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to View More

Abstract

The purpose of the present invention is to provide a pharmaceutical composition that comprises a hyaluronic acid derivative represented by formula (1) in the description or a pharmaceutically acceptable salt thereof, a method for producing the same, and a method for inhibiting the formation of diclofenac lactam from a compound represented by formula (1). Provided is a method for inhibiting the formation of diclofenac lactam from a compound represented by formula (1) in the description, said method comprising allowing the compound of formula (1) to coexist with component (A) that is at least one kind of compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1 to C3 monoalcohol, a C2 to C3 dialcohol, a C3 to C6 trialcohol, a polyalkylene glycol, gamma-lactone, polyvinylpyrrolidone, a chlorogenic acid, an alkyl sulfate and salts thereof. Also provided are a method for producing a pharmaceutical composition that comprises a compound represented by formula (1) and component (A), and a pharmaceutical composition produced thereby.

Description

technical field [0001] The present invention relates to pharmaceutical compositions comprising hyaluronic acid derivatives. Background technique [0002] Osteoarthritis (hereinafter, also referred to as "OA" in this specification), which is a dysfunction caused by joint pain and joint degeneration, is the most common joint disease in the world, and it has become a problem in the daily life of elderly people in particular. One of the leading causes of physical disability. Moreover, like OA, rheumatoid arthritis (hereinafter, also referred to as "RA" in this specification.) known as polyarthritis is known as a disease accompanied by joint swelling and pain. In RA, if the condition persists for a long time and the symptoms progress, the cartilage and bone are destroyed to cause degeneration and deformation, resulting in a physical disorder that causes problems in daily life such as narrowing the range of joint motion. [0003] Currently, preparations using hyaluronic acid and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/196A61P29/00A61K47/10A61K47/20A61K47/22A61K47/26A61K47/32A61K47/40A61K47/55A61K47/61
CPCA61P29/00A61K47/40A61K47/20A61K47/22A61K47/10A61K47/32A61K47/26A61K9/0019A61L27/54A61L2430/24A61L2300/412A61L2300/41A61K47/61A61K9/08A61K47/36A61K47/12A61K47/55A61K31/728A61K31/196A61P19/02A61K2300/00A61K47/02A61M5/178
Inventor 高畑千晶山下直哉国井直子星裕贵
Owner SEIKAGAKU KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com